

Valina L Dawson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3791571/publications.pdf>

Version: 2024-02-01

371
papers

75,874
citations

484

129
h-index

547

264
g-index

413
all docs

413
docs citations

413
times ranked

66529
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurotoxic reactive astrocytes are induced by activated microglia. <i>Nature</i> , 2017, 541, 481-487.	13.7	4,977
2	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
3	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	5.0	4,036
4	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. <i>Cell Death and Differentiation</i> , 2012, 19, 107-120.	5.0	2,144
5	Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor. <i>Science</i> , 2002, 297, 259-263.	6.0	1,671
6	Molecular Pathways of Neurodegeneration in Parkinson's Disease. <i>Science</i> , 2003, 302, 819-822.	6.0	1,530
7	PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 378-383.	3.3	1,415
8	MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE. <i>Annual Review of Neuroscience</i> , 2005, 28, 57-87.	5.0	1,111
9	From The Cover: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16842-16847.	3.3	1,084
10	Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. <i>Science</i> , 2001, 291, 2423-2428.	6.0	1,035
11	Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. <i>Nature Medicine</i> , 1999, 5, 1403-1409.	15.2	1,007
12	Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. <i>Nature Medicine</i> , 1997, 3, 1089-1095.	15.2	1,002
13	Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 13354-13359.	3.3	916
14	A novel neuronal messenger molecule in brain: The free radical, nitric oxide. <i>Annals of Neurology</i> , 1992, 32, 297-311.	2.8	837
15	Transneuronal Propagation of Pathologic α -Synuclein from the Gut to the Brain Models Parkinson's Disease. <i>Neuron</i> , 2019, 103, 627-641.e7.	3.8	830
16	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. <i>Cell Death and Differentiation</i> , 2015, 22, 58-73.	5.0	811
17	PARIS (ZNF746) Repression of PGC-1 β Contributes to Neurodegeneration in Parkinson's Disease. <i>Cell</i> , 2011, 144, 689-702.	13.5	796
18	S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function. <i>Science</i> , 2004, 304, 1328-1331.	6.0	736

#	ARTICLE	IF	CITATIONS
19	Genetic Animal Models of Parkinson's Disease. <i>Neuron</i> , 2010, 66, 646-661.	3.8	714
20	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. <i>Nature Medicine</i> , 2018, 24, 931-938.	15.2	712
21	Parkin ubiquitinates the α -synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. <i>Nature Medicine</i> , 2001, 7, 1144-1150.	15.2	710
22	Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 18314-18319.	3.3	655
23	T cells from patients with Parkinson's disease recognize α -synuclein peptides. <i>Nature</i> , 2017, 546, 656-661.	13.7	618
24	Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. <i>Nature</i> , 1995, 378, 383-386.	13.7	606
25	Kinase activity of mutant LRRK2 mediates neuronal toxicity. <i>Nature Neuroscience</i> , 2006, 9, 1231-1233.	7.1	587
26	Nitric Oxide Synthase in Models of Focal Ischemia. <i>Stroke</i> , 1997, 28, 1283-1288.	1.0	578
27	Poly(ADP-ribose) (PAR) polymer is a death signal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 18308-18313.	3.3	572
28	Diagnosis and treatment of Parkinson disease: molecules to medicine. <i>Journal of Clinical Investigation</i> , 2006, 116, 1744-1754.	3.9	538
29	Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. <i>Human Molecular Genetics</i> , 2007, 16, 223-232.	1.4	535
30	Pathological α -synuclein transmission initiated by binding lymphocyte-activation gene 3. <i>Science</i> , 2016, 353, .	6.0	521
31	Role of AIF in caspase-dependent and caspase-independent cell death. <i>Oncogene</i> , 2004, 23, 2785-2796.	2.6	490
32	Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation. <i>Journal of Neuroscience</i> , 2005, 25, 2002-2009.	1.7	489
33	Localization of LRRK2 to membranous and vesicular structures in mammalian brain. <i>Annals of Neurology</i> , 2006, 60, 557-569.	2.8	479
34	Synphilin-1 associates with α -synuclein and promotes the formation of cytosolic inclusions. <i>Nature Genetics</i> , 1999, 22, 110-114.	9.4	473
35	Nitric oxide neurotoxicity. <i>Journal of Chemical Neuroanatomy</i> , 1996, 10, 179-190.	1.0	460
36	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson's Disease. <i>Science Translational Medicine</i> , 2012, 4, 141ra90.	5.8	444

#	ARTICLE	IF	CITATIONS
37	Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. <i>Human Molecular Genetics</i> , 2001, 10, 919-926.	1.4	442
38	DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14807-14812.	3.3	435
39	Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. <i>Journal of Cell Biology</i> , 2002, 158, 507-517.	2.3	434
40	Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. <i>British Journal of Pharmacology</i> , 2014, 171, 2000-2016.	2.7	432
41	Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 259-264.	4.0	423
42	Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41. <i>Science</i> , 1996, 274, 1917-1921.	6.0	410
43	Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease. <i>Neurobiology of Disease</i> , 2000, 7, 240-250.	2.1	397
44	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18676-18681.	3.3	390
45	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. <i>Human Molecular Genetics</i> , 2005, 14, 2063-2073.	1.4	381
46	Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. <i>Human Molecular Genetics</i> , 2008, 17, 431-439.	1.4	379
47	Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 5774-5779.	3.3	365
48	Parkin-independent mitophagy requires Dc1 and maintains the integrity of mammalian heart and brain. <i>EMBO Journal</i> , 2014, 33, 2798-2813.	3.5	361
49	Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1-Dependent Cell Death (Parthanatos). <i>Science Signaling</i> , 2011, 4, ra20.	1.6	360
50	Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. <i>Nucleic Acids Research</i> , 2008, 36, 6959-6976.	6.5	359
51	Recent Advances in the Genetics of Parkinson's Disease. <i>Annual Review of Genomics and Human Genetics</i> , 2011, 12, 301-325.	2.5	355
52	Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. <i>Nature Cell Biology</i> , 2008, 10, 866-873.	4.6	353
53	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. <i>Nature Medicine</i> , 2010, 16, 998-1000.	15.2	342
54	Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. <i>PLoS ONE</i> , 2011, 6, e18568.	1.1	338

#	ARTICLE	IF	CITATIONS
55	Chapter 15 Nitric oxide in neurodegeneration. Progress in Brain Research, 1998, 118, 215-229.	0.9	336
56	Parthanatos, a messenger of death. Frontiers in Bioscience - Landmark, 2009, Volume, 1116.	3.0	330
57	Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Human Molecular Genetics, 1998, 7, 783-790.	1.4	329
58	Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos. Experimental Neurology, 2009, 218, 193-202.	2.0	327
59	Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Human Molecular Genetics, 2005, 14, 3801-3811.	1.4	321
60	Requirement for nitric oxide activation of p21ras/extracellular regulated kinase in neuronal ischemic preconditioning. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 436-441.	3.3	317
61	Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10744-10749.	3.3	317
62	Poly(ADP-ribose) drives pathologic α -synuclein neurodegeneration in Parkinson's disease. Science, 2018, 362, .	6.0	317
63	The role of parkin in familial and sporadic Parkinson's disease. Movement Disorders, 2010, 25, S32-9.	2.2	309
64	Parkin and PINK1: much more than mitophagy. Trends in Neurosciences, 2014, 37, 315-324.	4.2	309
65	Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17699-17704.	3.3	285
66	Mitochondrial and Nuclear Cross Talk in Cell Death. Annals of the New York Academy of Sciences, 2008, 1147, 233-241.	1.8	284
67	PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. Journal of Neurochemistry, 2004, 90, 1068-1075.	2.1	266
68	A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science, 2016, 354, .	6.0	266
69	Sulfhydration mediates neuroprotective actions of parkin. Nature Communications, 2013, 4, 1626.	5.8	265
70	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease. Molecular Neurodegeneration, 2020, 15, 20.	4.4	264
71	Manganese Superoxide Dismutase Protects nNOS Neurons from NMDA and Nitric Oxide-Mediated Neurotoxicity. Journal of Neuroscience, 1998, 18, 2040-2055.	1.7	258
72	Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death. Journal of Neuroscience, 2004, 24, 10963-10973.	1.7	258

#	ARTICLE	IF	CITATIONS
73	Understanding microRNAs in neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2009, 10, 837-841.	4.9	256
74	Neurobiology of Nitric Oxide. <i>Critical Reviews in Neurobiology</i> , 1996, 10, 291-316.	3.3	255
75	Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10209-10214.	3.3	253
76	MicroRNA-223 is neuroprotective by targeting glutamate receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18962-18967.	3.3	245
77	Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16691-16696.	3.3	241
78	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson's Disease. <i>Cell</i> , 2014, 157, 472-485.	13.5	239
79	Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glia cortical cultures. <i>Neuropharmacology</i> , 1994, 33, 1425-1430.	2.0	237
80	Å-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells. <i>Journal of Neuroscience</i> , 2005, 25, 5544-5552.	1.7	237
81	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. <i>Human Molecular Genetics</i> , 2005, 14, 71-84.	1.4	231
82	Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents. <i>Journal of Biological Chemistry</i> , 2007, 282, 16441-16453.	1.6	225
83	Neuroprotection by pharmacologic blockade of the GAPDH death cascade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3887-3889.	3.3	222
84	Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death. <i>Journal of Neuroscience</i> , 2005, 25, 7968-7978.	1.7	221
85	Mediation of cell death by poly(ADP-ribose) polymerase-1. <i>Pharmacological Research</i> , 2005, 52, 5-14.	3.1	218
86	In vitro and in vivo effects of genistein on murine alveolar macrophage TNF alpha production. <i>Cellular and Molecular Neurobiology</i> , 1998, 18, 667-682.	1.7	217
87	Free Radicals as Mediators of Neuronal Injury. <i>Cellular and Molecular Neurobiology</i> , 1998, 18, 667-682.	1.7	208
88	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11696-11701.	3.3	207
89	NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase. <i>Journal of Neuroscience</i> , 2000, 20, 8005-8011.	1.7	206
90	Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14103-14108.	3.3	205

#	ARTICLE	IF	CITATIONS
91	Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. <i>Human Molecular Genetics</i> , 2005, 14, 3885-3897.	1.4	201
92	Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. <i>Human Molecular Genetics</i> , 2005, 14, 2571-2586.	1.4	200
93	Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. <i>Cell Reports</i> , 2020, 32, 107908.	2.9	199
94	A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. <i>Journal of Neurochemistry</i> , 2003, 87, 1558-1567.	2.1	198
95	CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2897-2902.	3.3	195
96	Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila. <i>Journal of Neuroscience</i> , 2009, 29, 11257-11262.	1.7	193
97	Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21ras. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 5773-5778.	3.3	192
98	Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. <i>Nature Medicine</i> , 2011, 17, 692-699.	15.2	190
99	The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. <i>Scientific Reports</i> , 2014, 4, 4874.	1.6	188
100	Neuronal (type I) nitric oxide synthase regulates nuclear factor- κ B activity and immunologic (type II) nitric oxide synthase expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 2676-2680.	3.3	187
101	Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. <i>Neurobiology of Disease</i> , 2003, 14, 303-317.	2.1	185
102	The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. <i>Trends in Neurosciences</i> , 2001, 24, S7-S14.	4.2	184
103	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. <i>Nature Neuroscience</i> , 2013, 16, 1392-1400.	7.1	182
104	The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2. <i>Journal of Neuroscience</i> , 2008, 28, 3384-3391.	1.7	178
105	Nuclear Targeting of Mutant Huntingtin Increases Toxicity. <i>Molecular and Cellular Neurosciences</i> , 1999, 14, 121-128.	1.0	177
106	GTPase Activity Plays a Key Role in the Pathobiology of LRRK2. <i>PLoS Genetics</i> , 2010, 6, e1000902.	1.5	177
107	Microglia and astrocyte dysfunction in parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 144, 105028.	2.1	177
108	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. <i>Journal of Clinical Investigation</i> , 2003, 111, 145-151.	3.9	175

#	ARTICLE	IF	CITATIONS
109	Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. <i>Neuron</i> , 1990, 5, 199-208.	3.8	174
110	NITRIC OXIDE ACTIONS IN NEUROCHEMISTRY. <i>Neurochemistry International</i> , 1996, 29, 97-110.	1.9	174
111	<sc>M</sc>sp1<sc>ATAD</sc>1 maintains mitochondrial function by facilitating the degradation of mislocalized tail-anchored proteins. <i>EMBO Journal</i> , 2014, 33, 1548-1564.	3.5	172
112	Deadly Conversations: Nuclear-Mitochondrial Cross-Talk. <i>Journal of Bioenergetics and Biomembranes</i> , 2004, 36, 287-294.	1.0	169
113	Fyn kinase regulates misfolded α -synuclein uptake and NLRP3 inflammasome activation in microglia. <i>Journal of Experimental Medicine</i> , 2019, 216, 1411-1430.	4.2	169
114	Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 8617-8622.	3.3	168
115	The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. <i>Trends in Neurosciences</i> , 2001, 24, 7-14.	4.2	161
116	Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. <i>British Journal of Pharmacology</i> , 2018, 175, 192-222.	2.7	160
117	Neuroprotective and neurorestorative strategies for Parkinson's disease. <i>Nature Neuroscience</i> , 2002, 5, 1058-1061.	7.1	152
118	Role of nitric oxide in Parkinson's disease. , 2006, 109, 33-41.		150
119	ADP-ribosyltransferases, an update on function and nomenclature. <i>FEBS Journal</i> , 2022, 289, 7399-7410.	2.2	150
120	(Patho-)physiological relevance of <sc>PINK</sc>-dependent ubiquitin phosphorylation. <i>EMBO Reports</i> , 2015, 16, 1114-1130.	2.0	147
121	Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 5037-5042.	3.3	145
122	Autophagy-mediated clearance of aggresomes is not a universal phenomenon. <i>Human Molecular Genetics</i> , 2008, 17, 2570-2582.	1.4	143
123	α -Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. <i>Molecular Neurodegeneration</i> , 2018, 13, 1.	4.4	143
124	MicroRNAs in Parkinson's disease. <i>Journal of Chemical Neuroanatomy</i> , 2011, 42, 127-130.	1.0	142
125	Toward the human cellular microRNAome. <i>Genome Research</i> , 2017, 27, 1769-1781.	2.4	142
126	NITRIC OXIDE SYNTHASE: Role as a Transmitter/Mediator in the Brain and Endocrine System. <i>Annual Review of Medicine</i> , 1996, 47, 219-227.	5.0	141

#	ARTICLE	IF	CITATIONS
127	Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. <i>Hepatology</i> , 2004, 39, 403-411.	3.6	141
128	S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4900-4905.	3.3	141
129	Reprogramming cellular events by poly(ADP-ribose)-binding proteins. <i>Molecular Aspects of Medicine</i> , 2013, 34, 1066-1087.	2.7	141
130	PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. <i>Cell Reports</i> , 2017, 18, 918-932.	2.9	141
131	Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age. <i>Journal of Biological Chemistry</i> , 2003, 278, 48120-48128.	1.6	140
132	Bcl-x Is Required for Proper Development of the Mouse Substantia Nigra. <i>Journal of Neuroscience</i> , 2005, 25, 6721-6728.	1.7	140
133	Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. <i>Brain Research</i> , 2007, 1155, 208-219.	1.1	139
134	GBA1 deficiency negatively affects physiological α -synuclein tetramers and related multimers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 798-803.	3.3	139
135	Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. <i>Nature Medicine</i> , 1997, 3, 571-574.	15.2	138
136	Dynamic and redundant regulation of LRRK2 and LRRK1 expression. <i>BMC Neuroscience</i> , 2007, 8, 102.	0.8	135
137	Cyclic nucleotide dependent phosphorylation of neuronal nitric oxide synthase inhibits catalytic activity. <i>Neuropharmacology</i> , 1994, 33, 1245-1251.	2.0	134
138	Activation of tyrosine kinase c-Abl contributes to α -synuclein-induced neurodegeneration. <i>Journal of Clinical Investigation</i> , 2016, 126, 2970-2988.	3.9	133
139	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons. <i>ACS Chemical Biology</i> , 2011, 6, 1021-1028.	1.6	131
140	LRRK2 pathobiology in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2014, 131, 554-565.	2.1	131
141	Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases?. <i>Neurobiology of Aging</i> , 2006, 27, 524-529.	1.5	130
142	Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1999, 1455, 23-34.	1.8	129
143	FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 2425-2430.	3.3	128
144	NITRIC OXIDE: ROLE IN NEUROTOXICITY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, 305-308.	0.9	126

#	ARTICLE	IF	CITATIONS
145	Parkin-associated Parkinson's disease. <i>Cell and Tissue Research</i> , 2004, 318, 175-184.	1.5	126
146	Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy. <i>Journal of Neuroscience</i> , 2012, 32, 16503-16509.	1.7	124
147	Poly(ADP-Ribose) Polymerase Impairs Early and Long-Term Experimental Stroke Recovery. <i>Stroke</i> , 2002, 33, 1101-1106.	1.0	123
148	Nitric Oxide in Neuronal Degeneration. <i>Experimental Biology and Medicine</i> , 1996, 211, 33-40.	1.1	120
149	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in <i>Caenorhabditis elegans</i> and <i>Drosophila</i> Parkinson's disease models. <i>Human Molecular Genetics</i> , 2011, 20, 3933-3942.	1.4	120
150	Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 437-454.	4.2	120
151	Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. <i>Cell Death and Differentiation</i> , 2018, 25, 542-572.	5.0	120
152	Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder. <i>Nature Communications</i> , 2014, 5, 4930.	5.8	118
153	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. <i>Brain</i> , 2017, 140, 98-117.	3.7	116
154	Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine). <i>Journal of Neuroscience</i> , 2009, 29, 15846-15850.	1.7	114
155	Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. <i>Human Molecular Genetics</i> , 2014, 23, 2055-2077.	1.4	113
156	Apoptosis Inducing Factor and PARP-Mediated Injury in the MPTP Mouse Model of Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2003, 991, 132-139.	1.8	112
157	To die or grow: Parkinson's disease and cancer. <i>Trends in Neurosciences</i> , 2005, 28, 348-352.	4.2	110
158	Effects of Nitric Oxide on Neuroendocrine Function and Behavior. <i>Frontiers in Neuroendocrinology</i> , 1997, 18, 463-491.	2.5	107
159	37-kDa Laminin Receptor Precursor Modulates Cytotoxic Necrotizing Factor 1-mediated RhoA Activation and Bacterial Uptake. <i>Journal of Biological Chemistry</i> , 2003, 278, 16857-16862.	1.6	106
160	Molecular Mechanisms of Nitric Oxide Actions in the Brain. <i>Annals of the New York Academy of Sciences</i> , 1994, 738, 76-85.	1.8	103
161	Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. <i>Journal of Neurochemistry</i> , 2007, 100, 368-381.	2.1	101
162	Parkin mediates the degradation-independent ubiquitination of Hsp70. <i>Journal of Neurochemistry</i> , 2008, 105, 1806-1819.	2.1	101

#	ARTICLE	IF	CITATIONS
163	REVIEW — : Nitric Oxide: Actions and Pathological Roles. <i>Neuroscientist</i> , 1995, 1, 7-18.	2.6	100
164	mdx muscle pathology is independent of nNOS perturbation. <i>Human Molecular Genetics</i> , 1998, 7, 823-829.	1.4	99
165	Animal Models of Parkinson's Disease: Vertebrate Genetics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009324-a009324.	2.9	99
166	Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 1277-81.	3.3	99
167	Differential Susceptibility to Neurotoxicity Mediated by Neurotrophins and Neuronal Nitric Oxide Synthase. <i>Journal of Neuroscience</i> , 1997, 17, 4633-4641.	1.7	98
168	What causes cell death in Parkinson's disease?. <i>Annals of Neurology</i> , 2008, 64, S3-S15.	2.8	95
169	TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. <i>Brain</i> , 2015, 138, 3610-3622.	3.7	95
170	Inhibition of Neuronal Nitric Oxide Synthase Increases Aggressive Behavior in Mice. <i>Molecular Medicine</i> , 1997, 3, 610-616.	1.9	94
171	MicroRNA-132 dysregulation in <i>Toxoplasma gondii</i> infection has implications for dopamine signaling pathway. <i>Neuroscience</i> , 2014, 268, 128-138.	1.1	93
172	ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2. <i>Journal of Neuroscience</i> , 2012, 32, 3877-3886.	1.7	92
173	Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate. <i>Journal of Biological Chemistry</i> , 2006, 281, 16193-16196.	1.6	91
174	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. <i>Journal of Clinical Investigation</i> , 2003, 111, 145-151.	3.9	91
175	Cell Death Mechanisms of Neurodegeneration. <i>Advances in Neurobiology</i> , 2017, 15, 403-425.	1.3	90
176	Calpain activation is not required for AIF translocation in PARP1-dependent cell death (parthanatos). <i>Journal of Neurochemistry</i> , 2009, 110, 687-696.	2.1	89
177	The AAA+ ATPase Thorsen Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior. <i>Cell</i> , 2011, 145, 284-299.	13.5	88
178	Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. <i>European Journal of Neuroscience</i> , 2001, 13, 1683-1693.	1.2	87
179	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. <i>Molecular Neurodegeneration</i> , 2018, 13, 8.	4.4	87
180	Adult Conditional Knockout of PGC-1 β Leads to Loss of Dopamine Neurons. <i>ENeuro</i> , 2016, 3, ENEURO.0183-16.2016.	0.9	87

#	ARTICLE	IF	CITATIONS
181	Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of α -Synucleinopathy. <i>Journal of Neuroscience</i> , 2006, 26, 3685-3696.	1.7	86
182	Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. <i>Annals of Neurology</i> , 2001, 50, 6-16.	2.8	85
183	Neurodegenerative phenotypes in an A53T α -synuclein transgenic mouse model are independent of LRRK2. <i>Human Molecular Genetics</i> , 2012, 21, 2420-2431.	1.4	84
184	Neuroprotective Effect of α -Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production. <i>Stroke</i> , 2001, 32, 1613-1620.	1.0	83
185	Enhanced Autophagy from Chronic Toxicity of Iron and Mutant A53T α -Synuclein. <i>Journal of Biological Chemistry</i> , 2011, 286, 33380-33389.	1.6	82
186	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 78.	2.4	82
187	Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. <i>Neuroscience</i> , 1999, 90, 1483-1492.	1.1	81
188	EndoG is dispensable in embryogenesis and apoptosis. <i>Cell Death and Differentiation</i> , 2006, 13, 1147-1155.	5.0	81
189	Conditional transgenic mice expressing C-terminally truncated human α -synuclein (α Syn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. <i>Molecular Neurodegeneration</i> , 2009, 4, 34.	4.4	79
190	Nuclear Localization of a Non-caspase Truncation Product of Atrophia-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. <i>Journal of Biological Chemistry</i> , 2003, 278, 13047-13055.	1.6	78
191	Nanozyme scavenging ROS for prevention of pathologic α -synuclein transmission in Parkinson's disease. <i>Nano Today</i> , 2021, 36, 101027.	6.2	78
192	Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. <i>Life Sciences</i> , 1988, 42, 1933-1939.	2.0	77
193	The cell biology of Parkinson's disease. <i>Journal of Cell Biology</i> , 2021, 220, .	2.3	77
194	A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. <i>Journal of Neurochemistry</i> , 2002, 83, 186-192.	2.1	75
195	Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced Solubility Alterations. <i>Journal of Biological Chemistry</i> , 2007, 282, 12310-12318.	1.6	75
196	Abnormal Localization of Leucine-Rich Repeat Kinase 2 to the Endosomal-Lysosomal Compartment in Lewy Body Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 994-1005.	0.9	75
197	Parkin Plays a Role in Sporadic Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2014, 13, 69-71.	0.8	74
198	Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. <i>Molecular Brain Research</i> , 2005, 134, 103-108.	2.5	71

#	ARTICLE	IF	CITATIONS
199	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1635-1640.	3.3	70
200	Outer Mitochondrial Membrane Localization of Apoptosis-Inducing Factor: Mechanistic Implications for Release. <i>ASN Neuro</i> , 2009, 1, AN20090046.	1.5	69
201	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 365-373.	4.0	69
202	Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra. <i>Experimental Neurology</i> , 1991, 111, 282-292.	2.0	68
203	Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. <i>Annals of Neurology</i> , 1995, 37, 115-118.	2.8	68
204	The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. <i>Movement Disorders</i> , 2019, 34, 959-969.	2.2	68
205	c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential. <i>Journal of Parkinson's Disease</i> , 2017, 7, 589-601.	1.5	67
206	LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization. <i>PLoS ONE</i> , 2013, 8, e77198.	1.1	66
207	Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. <i>Science Translational Medicine</i> , 2016, 8, 333ra48.	5.8	66
208	Nitric Oxide Signaling in Neurodegeneration and Cell Death. <i>Advances in Pharmacology</i> , 2018, 82, 57-83.	1.2	65
209	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. <i>Neurobiology of Disease</i> , 2007, 26, 312-322.	2.1	64
210	STING mediates neurodegeneration and neuroinflammation in nigrostriatal α -synucleinopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2118819119.	3.3	64
211	Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease. <i>Neuron</i> , 2022, 110, 2422-2437.e9.	3.8	64
212	Normalization of subtype-specific muscarinic receptor binding in the denervated hippocampus by septodiagonal band grafts. <i>Experimental Neurology</i> , 1989, 106, 115-124.	2.0	63
213	Differential Effect of PARP-2 Deletion on Brain Injury after Focal and Global Cerebral Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 135-141.	2.4	63
214	Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. <i>International Review of Cell and Molecular Biology</i> , 2020, 353, 1-29.	1.6	63
215	Physiological and Toxicological Actions of Nitric Oxide in the Central Nervous System. <i>Advances in Pharmacology</i> , 1995, 34, 323-342.	1.2	62
216	Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone. <i>Brain Research</i> , 1997, 769, 66-70.	1.1	62

#	ARTICLE	IF	CITATIONS
217	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. <i>Molecular Neurodegeneration</i> , 2017, 12, 32.	4.4	62
218	Pathological Endogenous $\hat{\alpha}$ -Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. <i>Stem Cell Reports</i> , 2018, 10, 356-365.	2.3	61
219	Determinants of seeding and spreading of $\hat{\alpha}$ -synuclein pathology in the brain. <i>Science Advances</i> , 2020, 6, .	4.7	61
220	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. <i>Neurobiology of Disease</i> , 2014, 71, 345-358.	2.1	59
221	Mechanistic basis for receptor-mediated pathological $\hat{\alpha}$ -synuclein fibril cell-to-cell transmission in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	59
222	PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. <i>Molecular Neurodegeneration</i> , 2020, 15, 17.	4.4	58
223	Identification and analysis of plasticity-induced late-response genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2145-2150.	3.3	57
224	Resistance to MPTP-Neurotoxicity in $\hat{\alpha}$ -Synuclein Knockout Mice Is Complemented by Human $\hat{\alpha}$ -Synuclein and Associated with Increased $\hat{\alpha}$ -Synuclein and Akt Activation. <i>PLoS ONE</i> , 2011, 6, e16706.	1.1	57
225	Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats. <i>Stroke</i> , 1999, 30, 1279-1285.	1.0	56
226	Protein Microarray Characterization of the S-Nitrosoproteome. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 63-72.	2.5	56
227	Neuronal ischaemic preconditioning. <i>Trends in Pharmacological Sciences</i> , 2000, 21, 423-424.	4.0	55
228	Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. <i>Free Radical Biology and Medicine</i> , 2009, 47, 1049-1056.	1.3	55
229	Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes. <i>Experimental Neurology</i> , 2017, 298, 191-201.	2.0	55
230	Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. <i>Autophagy</i> , 2008, 4, 251-253.	4.3	54
231	Botch Promotes Neurogenesis by Antagonizing Notch. <i>Developmental Cell</i> , 2012, 22, 707-720.	3.1	54
232	Parkinson's disease genetic mutations increase cell susceptibility to stress: Mutant $\hat{\alpha}$ -synuclein enhances H ₂ O ₂ - and Sin-1-induced cell death. <i>Neurobiology of Aging</i> , 2007, 28, 1709-1717.	1.5	53
233	A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. <i>Brain</i> , 2018, 141, 651-661.	3.7	52
234	Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia. <i>Journal of Neurochemistry</i> , 2010, 113, 1012-1022.	2.1	51

#	ARTICLE	IF	CITATIONS
235	Role for the Ubiquitin-Proteasome System in Parkinson's Disease and Other Neurodegenerative Brain Amyloidoses. <i>NeuroMolecular Medicine</i> , 2003, 4, 95-108.	1.8	50
236	The interplay of microRNA and neuronal activity in health and disease. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 136.	1.8	50
237	Models of LRRK2-Associated Parkinson's Disease. <i>Advances in Neurobiology</i> , 2017, 14, 163-191.	1.3	50
238	BAD Is a Pro-survival Factor Prior to Activation of Its Pro-apoptotic Function. <i>Journal of Biological Chemistry</i> , 2004, 279, 42240-42249.	1.6	48
239	Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2. <i>Journal of Biological Chemistry</i> , 2010, 285, 29569-29576.	1.6	48
240	Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. <i>Stem Cell Reports</i> , 2020, 15, 629-645.	2.3	48
241	Neuronal Activity Regulates Hippocampal miRNA Expression. <i>PLoS ONE</i> , 2011, 6, e25068.	1.1	48
242	Activation mechanisms of the E3 ubiquitin ligase parkin. <i>Biochemical Journal</i> , 2017, 474, 3075-3086.	1.7	47
243	Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 125.	2.4	47
244	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. <i>Brain</i> , 2019, 142, 2380-2401.	3.7	46
245	Promising disease-modifying therapies for Parkinson's disease. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	46
246	Ganglioside Regulation of AMPA Receptor Trafficking. <i>Journal of Neuroscience</i> , 2014, 34, 13246-13258.	1.7	45
247	Synaptic Plasticity onto Dopamine Neurons Shapes Fear Learning. <i>Neuron</i> , 2017, 93, 425-440.	3.8	45
248	Stroke Outcome in Double-Mutant Antioxidant Transgenic Mice. <i>Stroke</i> , 2000, 31, 2685-2691.	1.0	44
249	NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2446-2456.	3.9	42
250	Early-onset Parkinson's disease due to PINK1 p.Q456X mutation – Clinical and functional study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1274-1278.	1.1	41
251	Influence of duration of focal cerebral ischemia and neuronal nitric oxide synthase on translocation of apoptosis-inducing factor to the nucleus. <i>Neuroscience</i> , 2007, 144, 56-65.	1.1	40
252	Precision therapy for a new disorder of AMPA receptor recycling due to mutations in <i>ATAD1</i> . <i>Neurology: Genetics</i> , 2017, 3, e130.	0.9	40

#	ARTICLE	IF	CITATIONS
253	Involvement of poly ADP ribosyl polymerase-1 in acute but not chronic zinc toxicity. <i>European Journal of Neuroscience</i> , 2003, 18, 1402-1409.	1.2	39
254	Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. <i>Stem Cells Translational Medicine</i> , 2019, 8, 112-123.	1.6	39
255	S-nitrosylation in Parkinson's Disease and Related Neurodegenerative Disorders. <i>Methods in Enzymology</i> , 2005, 396, 139-150.	0.4	38
256	Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. <i>Cell Stem Cell</i> , 2020, 27, 633-645.e7.	5.2	38
257	New insights into Parkinson's disease. <i>Journal of Neurology</i> , 2003, 250, 1-1.	1.8	37
258	Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. <i>Brain Research Bulletin</i> , 1990, 25, 903-912.	1.4	36
259	Advances in Neuronal Cell Death 2007. <i>Stroke</i> , 2008, 39, 286-288.	1.0	36
260	LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 90-97.	1.0	36
261	PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease. <i>Cell</i> , 2022, 185, 1943-1959.e21.	13.5	36
262	The Cast of Molecular Characters in Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2003, 991, 80-92.	1.8	35
263	Proneural Transcription Factor Atoh1 Drives Highly Efficient Differentiation of Human Pluripotent Stem Cells Into Dopaminergic Neurons. <i>Stem Cells Translational Medicine</i> , 2014, 3, 888-898.	1.6	35
264	Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. <i>Neuroscience</i> , 2007, 148, 198-211.	1.1	34
265	Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. <i>Human Molecular Genetics</i> , 2012, 21, 163-174.	1.4	34
266	New synaptic and molecular targets for neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 51-60.	2.2	34
267	Identification through high-throughput screening of 4'-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos. <i>British Journal of Pharmacology</i> , 2013, 169, 1263-1278.	2.7	34
268	DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders. <i>Translational Psychiatry</i> , 2018, 8, 76.	2.4	34
269	Glutamate-stimulated calcium activation of Ras/Erk pathway mediated by nitric oxide. <i>Diabetes Research and Clinical Practice</i> , 1999, 45, 113-115.	1.1	33
270	Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 647-652.	3.3	32

#	ARTICLE	IF	CITATIONS
271	Functional Identification of Neuroprotective Molecules. <i>PLoS ONE</i> , 2010, 5, e15008.	1.1	31
272	Overexpression of Parkinsonâ€™s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and Î±-Synuclein Pathology. <i>ENeuro</i> , 2017, 4, ENEURO.0004-17.2017.	0.9	31
273	PARIS farnesylation prevents neurodegeneration in models of Parkinsonâ€™s disease. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	30
274	The involvement of nitric oxide in the enhanced expression of Î¼-opioid receptors during intestinal inflammation in mice. <i>British Journal of Pharmacology</i> , 2005, 145, 758-766.	2.7	29
275	Botch Is a Î³-Glutamyl Cyclotransferase that Deglycinates and Antagonizes Notch. <i>Cell Reports</i> , 2014, 7, 681-688.	2.9	29
276	Lymphocyte Activation Gene 3 (Lag3) Contributes to Î±-Synucleinopathy in Î±-Synuclein Transgenic Mice. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 656426.	1.8	29
277	Targeting Parthanatos in Ischemic Stroke. <i>Frontiers in Neurology</i> , 2021, 12, 662034.	1.1	28
278	The Orphan Nuclear Receptor, Steroidogenic Factor 1, Regulates Neuronal Nitric Oxide Synthase Gene Expression in Pituitary Gonadotropes. <i>Molecular Endocrinology</i> , 2002, 16, 2828-2839.	3.7	27
279	The genetics of Parkinsonâ€™s disease. <i>Current Neurology and Neuroscience Reports</i> , 2002, 2, 439-446.	2.0	27
280	Lessons from Drosophila Models of DJ-1 Deficiency. <i>Science of Aging Knowledge Environment: SAGE KE</i> , 2006, 2006, pe2-pe2.	0.9	27
281	The impact of genetic research on our understanding of Parkinsonâ€™s disease. <i>Progress in Brain Research</i> , 2010, 183, 21-41.	0.9	26
282	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinsonâ€™s disease. <i>Neuron</i> , 2021, 109, 3758-3774.e11.	3.8	26
283	Two approaches reveal a new paradigm of â€œswitchable or genetics-influenced allele-specific DNA methylationâ€™ with potential in human disease. <i>Cell Discovery</i> , 2017, 3, 17038.	3.1	25
284	gp120 neurotoxicity in primary cortical cultures. <i>Advances in Neuroimmunology</i> , 1994, 4, 167-173.	1.8	24
285	MiR-223 regulates the differentiation of immature neurons. <i>Molecular and Cellular Therapies</i> , 2014, 2, 18.	0.2	24
286	Neonatal Stroke in Mice Causes Long-Term Changes in Neuronal Notch-2 Expression That May Contribute to Prolonged Injury. <i>Stroke</i> , 2010, 41, S64-71.	1.0	23
287	Motor Neuron Death in ALS: Programmed by Astrocytes?. <i>Neuron</i> , 2014, 81, 961-963.	3.8	23
288	Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants. <i>Brain Research</i> , 1991, 540, 145-152.	1.1	22

#	ARTICLE	IF	CITATIONS
289	Alterations in cortical muscarinic receptors following cholinotoxin (AF64A) lesion of the rat nucleus basalis magnocellularis. <i>Neurobiology of Aging</i> , 1992, 13, 25-32.	1.5	22
290	Impaired Ovulation in Mice with Targeted Deletion of the Neuronal Isoform of Nitric Oxide Synthase. <i>Molecular Medicine</i> , 1998, 4, 658-664.	1.9	22
291	The Road to Survival Goes through PARC. <i>Cell Cycle</i> , 2005, 4, 397-399.	1.3	21
292	LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. <i>Biochemical Society Transactions</i> , 2012, 40, 1074-1079.	1.6	21
293	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in α -Synuclein-Based Mouse Models of Parkinson's Disease. <i>Journal of Proteome Research</i> , 2021, 20, 3428-3443.	1.8	21
294	Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems. <i>Neuroscientist</i> , 1998, 4, 96-112.	2.6	20
295	Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function". <i>Science</i> , 2005, 308, 1870c-1870c.	6.0	20
296	Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	20
297	Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1982-1993.	2.4	20
298	Abberant protein synthesis in G2019S LRRK2 <i>Drosophila</i> Parkinson disease-related phenotypes. <i>Fly</i> , 2014, 8, 165-169.	0.9	19
299	Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 299, R215-R221.	0.9	18
300	Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological α -synuclein. <i>Cell Reports</i> , 2022, 38, 110358.	2.9	18
301	Hippocampal muscarinic supersensitivity after AF64A medial septal lesion excludes M1 receptors. <i>Brain Research Bulletin</i> , 1990, 25, 311-317.	1.4	17
302	Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities. <i>ENeuro</i> , 2019, 6, ENEURO.0148-19.2019.	0.9	16
303	Parkin: clinical aspects and neurobiology. <i>Clinical Neuroscience Research</i> , 2001, 1, 467-482.	0.8	15
304	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. <i>ELife</i> , 2021, 10, .	2.8	15
305	High-Content Genome-Wide RNAi Screen Reveals <i>CCR3</i> as a Key Mediator of Neuronal Cell Death. <i>ENeuro</i> , 2016, 3, ENEURO.0185-16.2016.	0.9	15
306	Genetics of Parkinson's disease: What do mutations in DJ-1 tell us?. <i>Annals of Neurology</i> , 2003, 54, 281-282.	2.8	14

#	ARTICLE	IF	CITATIONS
307	Recent advances in our understanding of Parkinson's disease. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 427-433.	0.8	14
308	What have Genetically Engineered Mice Taught Us About Ischemic Injury?. <i>Current Molecular Medicine</i> , 2004, 4, 207-225.	0.6	14
309	Receptor Alterations in Subcortical Structures after Bilateral Middle Cerebral Artery Infarction of the Cerebral Cortex. <i>Experimental Neurology</i> , 1994, 128, 88-96.	2.0	13
310	Ironing out tau's role in parkinsonism. <i>Nature Medicine</i> , 2012, 18, 197-198.	15.2	13
311	Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. <i>Brain</i> , 2021, 144, 3674-3691.	3.7	13
312	SnapShot: Pathogenesis of Parkinson's Disease. <i>Cell</i> , 2009, 139, 440.e1-440.e2.	13.5	12
313	Lysosomal Enzyme Glucocerebrosidase Protects against A β 1-42 Oligomer-Induced Neurotoxicity. <i>PLoS ONE</i> , 2015, 10, e0143854.	1.1	12
314	AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF. <i>Cell Reports</i> , 2020, 33, 108329.	2.9	12
315	USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing. <i>Nucleic Acids Research</i> , 2021, 49, 11083-11102.	6.5	12
316	Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinson's disease. <i>Science Advances</i> , 2022, 8, eabh1824.	4.7	12
317	A Lysosomal Lair for a Pathogenic Protein Pair. <i>Science Translational Medicine</i> , 2011, 3, 91ps28.	5.8	11
318	Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke. <i>PLoS ONE</i> , 2020, 15, e0231978.	1.1	11
319	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. <i>Pharmacological Reviews</i> , 2021, 73, 1204-1268.	7.1	11
320	Nitric Oxide Synthase Inhibitors. <i>CNS Drugs</i> , 1996, 6, 351-357.	2.7	10
321	The AAA+ATPase Thorase is neuroprotective against ischemic injury. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1836-1848.	2.4	10
322	Development of a novel method for the quantification of tyrosine 39 phosphorylated α - and β -synuclein in human cerebrospinal fluid. <i>Clinical Proteomics</i> , 2020, 17, 13.	1.1	10
323	Maiming mitochondria in familial ALS. <i>Nature Medicine</i> , 2004, 10, 905-906.	15.2	9
324	Reduction of functional N-methyl-d-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. <i>Journal of Neurochemistry</i> , 2001, 76, 1386-1394.	2.1	8

#	ARTICLE	IF	CITATIONS
325	Taming the clot-buster tPA. <i>Nature Medicine</i> , 2006, 12, 993-994.	15.2	8
326	Molecular Mediation of Prion-like α -Synuclein Fibrillation from Toxic PFFs to Nontoxic Species. <i>ACS Applied Bio Materials</i> , 2020, 3, 6096-6102.	2.3	8
327	CYFIP1 Dosages Exhibit Divergent Behavioral Impact via Diametric Regulation of NMDA Receptor Complex Translation in Mouse Models of Psychiatric Disorders. <i>Biological Psychiatry</i> , 2022, 92, 815-826.	0.7	8
328	Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in <i>Drosophila</i> dissects recognition of multiple PPAR- γ associated gene regulation. <i>Scientific Reports</i> , 2021, 11, 21500.	1.6	8
329	Histochemical Analysis of Nitric Oxide Synthase by NADPH Diaphorase Staining. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , 1999, 1, Unit 10.6.	1.1	7
330	Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons. <i>STAR Protocols</i> , 2021, 2, 100405.	0.5	7
331	Usp16: key controller of stem cells in Down syndrome. <i>EMBO Journal</i> , 2013, 32, 2788-2789.	3.5	6
332	Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. <i>ENeuro</i> , 2021, 8, ENEURO.0310-21.2021.	0.9	6
333	LRRK2 pathobiology in Parkinson's disease – virtual inclusion. <i>Journal of Neurochemistry</i> , 2016, 139, 75-76.	2.1	5
334	Neurotoxic Actions and Mechanisms of Nitric Oxide. , 2000, , 695-710.		5
335	Nitric Oxide Toxicity in Central Nervous System Cultures. <i>Methods in Neurosciences</i> , 1996, 30, 26-43.	0.5	4
336	Generation of isoform-specific antibodies to nitric oxide synthases. <i>Methods in Enzymology</i> , 1996, 268, 349-358.	0.4	4
337	Gene therapy to the rescue in Parkinson's disease. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 103-105.	4.0	4
338	Mining for survival genes. <i>Biochemical Society Transactions</i> , 2006, 34, 1307-1309.	1.6	4
339	PARP and the Release of Apoptosis-Inducing Factor from Mitochondria. , 2006, , 103-117.		4
340	Influence of Nitric Oxide on Neuroendocrine Function and Behavior. , 2000, , 429-438.		4
341	Recent advances in preventing neurodegenerative diseases. <i>Faculty Reviews</i> , 2021, 10, 81.	1.7	4
342	Genomics-Proteomics and Stroke: Introduction. <i>Stroke</i> , 2004, 35, 2731-2734.	1.0	3

#	ARTICLE	IF	CITATIONS
343	AlF3 splicing switch triggers neurodegeneration. <i>Molecular Neurodegeneration</i> , 2021, 16, 25.	4.4	3
344	NADPH Diaphorase Staining. <i>Methods in Neurosciences</i> , 1996, 31, 62-67.	0.5	2
345	Function of Nitric Oxide in Neuronal Cell Death. <i>Methods in Neurosciences</i> , 1996, , 228-240.	0.5	2
346	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2017, 140, e33-e33.	3.7	2
347	Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms. , 2018, , 3-17.		2
348	Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson's Disease. <i>Methods in Molecular Biology</i> , 2012, 795, 45-54.	0.4	2
349	Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain. <i>Bio-protocol</i> , 2020, 10, e3746.	0.2	2
350	Waiting for PARIS: A Biological Target in Search of a Drug. <i>Journal of Parkinson's Disease</i> , 2021, , 1-9.	1.5	2
351	A high-affinity cocaine binding site associated with the brain acid soluble protein 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200545119.	3.3	2
352	Identification and Evaluation of NO-Regulated Genes by Differential Analysis of Primary cDNA Library Expression (DAzLE). <i>Methods in Enzymology</i> , 2005, 396, 359-368.	0.4	1
353	Reply: ATAD1 encephalopathy and stiff baby syndrome: a recognizable clinical presentation. <i>Brain</i> , 2018, 141, e50-e50.	3.7	1
354	LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8. <i>Cells</i> , 2021, 10, 203.	1.8	1
355	Parthanatos. , 2008, , 143-156.		1
356	Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms. , 2010, , 79-88.		1
357	Overview of the Pathway and Functions of Nitric Oxide. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , 1999, 00, Unit 10.1.	1.1	0
358	Mechanisms of ischemic tolerance. , 2002, , 58-71.		0
359	Poly (ADP-ribose) polymerase and brain ischemia. <i>International Congress Series</i> , 2003, 1252, 21-29.	0.2	0
360	The role of nitric oxide and PARP in neuronal cell death. , 2005, , 146-156.		0

#	ARTICLE	IF	CITATIONS
361	Parkinson Disease: Molecular Insights. , 2007, , 221-239.		0
362	Intracellular Signaling. , 2016, , 80-89.		0
363	The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. Juntendo Medical Journal, 2018, 64, 17-30.	0.1	0
364	Intracellular Signaling. , 2022, , 74-81.e5.		0
365	Intracellular Signaling: Mediators and Protective Responses. , 2004, , 895-902.		0
366	Genetics Of Parkinsonâ€™s Disease. Neurological Disease and Therapy, 2005, , 611-631.	0.0	0
367	Genetic Models of Familial Parkinson's Disease. , 2008, , 225-236.		0
368	Intracellular Signaling: Mediators and Protective Responses. , 2011, , 154-161.		0
369	Reversal of Nigrostriatal-Lesion-Induced Receptor Alterations by Grafting of Fetal Mesencephalic Dopaminergic Neurons. Advances in Experimental Medicine and Biology, 1991, 287, 221-235.	0.8	0
370	Nitric Oxide Neurotoxicity in Primary Neuronal Cultures. , 1995, , 3-15.		0
371	Nitric Oxide Actions in the Nervous System. , 1996, , 247-262.		0